FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

In Partnership With:

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center, University of Miami</b>

Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Mikkael A. Sekeres, MD, about the FDA approval of quizartinib (Vanflyta) in combination with chemotherapy in patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia (AML). Dr Sekeres is a professor of medicine and chief of the Division of Hematology, Leukemia Section, at the University of Miami Health System in Florida.

On July 20, 2023, the FDA approved quizartinib plus standard cytarabine and anthracycline induction and cytarabine consolidation and as maintenance monotherapy after consolidation chemotherapy, for adult patients with newly diagnosed, FLT3-ITD–positive AML. This approval was supported by findings from the phase 3 QuANTUM-First trial (NCT02668653), in which, at a median follow-up of 32.9 months (interquartile range, 31.9-45.8), patients who received quizartinib plus chemotherapy achieved a median overall survival of 31.9 months (95% CI, 21.0-not estimable) vs 15.1 months (95% CI, 13.2-26.2) with placebo plus chemotherapy (HR, 0.78; 95% CI, 0.62-0.98; 2-sided P = .0324).

In our exclusive interview, Dr Sekeres discussed the significance of this approval, key efficacy and safety data from QuANTUM-First, and how this quizartinib regimen addresses an unmet need for older patients with FLT3-ITD–positive AML.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.